TECX vs. ARQT, ADPT, EWTX, SDGR, BHVN, MESO, SPRY, ETNB, EVO, and ANIP
Should you be buying Tectonic Therapeutic stock or one of its competitors? The main competitors of Tectonic Therapeutic include Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), Edgewise Therapeutics (EWTX), Schrödinger (SDGR), Biohaven (BHVN), Mesoblast (MESO), ARS Pharmaceuticals (SPRY), 89bio (ETNB), Evotec (EVO), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.
Tectonic Therapeutic vs. Its Competitors
Tectonic Therapeutic (NASDAQ:TECX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, community ranking, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.
Tectonic Therapeutic presently has a consensus target price of $82.33, suggesting a potential upside of 315.82%. Arcutis Biotherapeutics has a consensus target price of $18.80, suggesting a potential upside of 37.53%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, research analysts clearly believe Tectonic Therapeutic is more favorable than Arcutis Biotherapeutics.
Arcutis Biotherapeutics received 59 more outperform votes than Tectonic Therapeutic when rated by MarketBeat users. However, 100.00% of users gave Tectonic Therapeutic an outperform vote while only 68.22% of users gave Arcutis Biotherapeutics an outperform vote.
Tectonic Therapeutic has a beta of 3.25, suggesting that its stock price is 225% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.
In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 3 mentions for Tectonic Therapeutic. Arcutis Biotherapeutics' average media sentiment score of 0.90 beat Tectonic Therapeutic's score of 0.32 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
Tectonic Therapeutic has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -60.95%. Tectonic Therapeutic's return on equity of -30.13% beat Arcutis Biotherapeutics' return on equity.
Tectonic Therapeutic has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.
62.6% of Tectonic Therapeutic shares are held by institutional investors. 38.0% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Tectonic Therapeutic beats Arcutis Biotherapeutics on 13 of the 18 factors compared between the two stocks.
Get Tectonic Therapeutic News Delivered to You Automatically
Sign up to receive the latest news and ratings for TECX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tectonic Therapeutic Competitors List
Related Companies and Tools
This page (NASDAQ:TECX) was last updated on 6/18/2025 by MarketBeat.com Staff
Buy TECX Stock Free TECX Stock Alerts